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Background: Adverse gestational outcomes such as preeclampsia (PE) and intrauterine growth restriction (IUGR)
are associated with placental insufficiency. Normal placental development relies on the insulin-like growth factors -I
and -II (IGF-I and -II), in part to stimulate trophoblast proliferation and extravillous trophoblast (EVT) migration. The
insulin-like growth factor binding proteins (IGFBPs) modulate the bioavailability of IGFs in various ways, including
sequestration, potentiation, and/or increase in half-life. The roles of IGFBP-4 and −5 in the placenta are unknown, despite
consistent associations between pregnancy complications and the levels of two IGFBP-4 and/or −5 proteases,
pregnancy-associated plasma protein -A and -A2 (PAPP-A and PAPP-A2). The primary objective of this study was
to elucidate the effects of IGFBP-4 and −5 on IGF-I and IGF-II in a model of EVT migration. A related objective was
to determine the timing and location of IGFBP-4 and −5 expression in the placental villi.
Methods: We used wound healing assays to examine the effects of IGFBP-4 and −5 on the migration of HTR-8/SVneo
cells following 4 hours of serum starvation and 24 hours of treatment. Localization of IGFBP-4, −5 and PAPP-A2 was
assessed by immunohistochemical staining of first trimester placental sections.
Results: 2 nM IGF-I and -II each increased HTR-8/SVneo cell migration with IGF-I increasing migration significantly more
than IGF-II. IGFBP-4 and −5 showed different levels of inhibition against IGF-I. 20 nM IGFBP-4 completely blocked
the effects of 2 nM IGF-I, while 20 nM IGFBP-5 significantly reduced the effects of 2 nM IGF-I, but not to control
levels. Either 20 nM IGFBP-4 or 20 nM IGFBP-5 completely blocked the effects of 2 nM IGF-II. Immunohistochemistry
revealed co-localization of IGFBP-4, IGFBP-5 and PAPP-A2 in the syncytiotrophoblast layer of first trimester placental
villi as early as 5 weeks of gestational age.
Conclusions: IGFBP-4 and −5 show different levels of inhibition on the migration-stimulating effects of IGF-I and
IGF-II, suggesting different roles for PAPP-A and PAPP-A2. Moreover, co-localization of the pappalysins and their
substrates within placental villi suggests undescribed roles of these molecules in early placental development.
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Trophoblast migrationBackground
Adverse gestational outcomes such as preeclampsia (PE)
and intrauterine growth restriction (IUGR) are thought
to be caused, at least in part, by deficiencies in processes
critical to placental development, including extravillous
trophoblast (EVT) invasion. EVT invade the maternal
decidua and replace the endothelium of uterine spiral* Correspondence: julian_christians@sfu.ca
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unless otherwise stated.arteries, thus increasing vessel diameter to ensure adequate
blood flow required for oxygen and nutrient delivery to the
placenta [1,2]. In both human villous explants and primary
trophoblast cultures, insulin-like growth factors I and II
(IGF-I and IGF-II, respectively), stimulate trophoblast pro-
liferation and EVT migration [3,4].
The bioavailability of IGF-I and -II is modulated by six
insulin-like growth factor-binding proteins (IGFBPs)
[3,5,6], with the release of the IGFs generally achieved
through proteolysis of the IGFBPs [7]. In addition toLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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IGFBPs increase the half-life of IGFs, concentrate them
in particular regions and/or potentiate their effects [8].
Furthermore, IGFBP-1, IGFBP-2, IGFBP-3 and IGFBP-5
all exert IGF-independent effects in a variety of cell
models and tissues [3,6,9]. For example, IGFBP-1 stimu-
lates migration in an IGF-independent manner in HTR-8/
SVneo cells, an immortalized trophoblast cell line com-
monly used to model EVT migration and invasion [10]. In
BeWo cells, an immortalized choriocarcinoma cell line
commonly used to model the villous cytotrophoblast,
IGFBP-3 inhibits proliferation in an IGF-independent
manner [11]. The proteolytic fragments of cleaved IGFBP-
3 and −5 have also been shown to have effects in other
systems [12-14].
The pappalysins, pregnancy-associated plasma proteins-A
and -A2 (PAPP-A and PAPP-A2, respectively), are two
IGFBP proteases that have been consistently associated
with a range of pregnancy complications. PAPP-A is a
protease of IGFBP-4 and −5 that is produced by the
placenta [15] and circulates in the maternal blood at
high levels during pregnancy. Abnormally low levels of
PAPP-A in the first trimester have frequently been associ-
ated with increased risk of PE and IUGR [16]. Pregnancy-
associated plasma protein-A2 (PAPP-A2) shares 45%
amino acid identity with PAPP-A, cleaves IGFBP-5 but not
IGFBP-4, and is also produced by the syncytiotrophoblast
and released into the maternal circulation during preg-
nancy [17]. PAPP-A2 levels in the placenta and maternal
circulation are higher at term in preeclamptic pregnan-
cies and pregnancies with severe fetal growth restriction
[18-21], and PAPP-A2 levels are also elevated in the
first-trimester maternal serum of pregnancies that subse-
quently develop preeclampsia [22].
The mechanistic links between circulating pappalysin
levels and pregnancy complications, and whether altered
pappalysin expression plays a causal role in placental
pathologies, remain unknown. However, whatever role
the pappalysins play in placental development and physi-
ology likely involves their IGFBP substrates, IGFBP-4
and −5. While IGFBP-1 is the most abundant IGFBP
within the maternal decidua [23] and is relatively well-
studied, the roles of IGFBP-4 and −5 in placental devel-
opment have received little attention.
The purpose of this study was to investigate whether
the pappalysins might influence EVT migration and inva-
sion through effects on IGF availability and/or other ac-
tions of the IGFBPs. We employed a well-established
model of first trimester EVT to examine the effects of ex-
ogenous IGFBP-4 and −5 on the migration-stimulating ef-
fects of IGF-I and IGF-II. We focused primarily on the
inhibition of the migration, but also tested for potentiation
and IGF-independent effects. The IGFBPs are known to
be expressed in the maternal decidua [23] and thereforeare well positioned to regulate EVT invasion. However, to
examine whether IGFBP-4 and −5 might also regulate
processes within the villi, we examined the expression
of these binding proteins in first-trimester villi using
immunohistochemistry.
Methods
Cell lines and cell culture
HTR-8/SVneo cells, an immortalized cell line that is a
well-established model of first trimester human tropho-
blasts, were obtained from Dr. Charles Graham (Queen’s
University, Kingston, ON, Canada) [24,25]. Cells were
cultured in RPMI 1640 medium supplemented with 10%
fetal bovine serum, 100 U/mL of penicillin, and 100 U/mL
of streptomycin at 37°C in a humidified atmosphere of 5%
CO2. Cell culture media and reagents were purchased from
Life Technologies (Burlington, ON, Canada).
HTR-8/SVneo cell wounding assay
HTR-8/SVneo cells were seeded at a density of 40,000
cells per well in 24-well polystyrene tissue culture plates
and allowed to grow to confluence before serum starving
for at least 4 hours. Wounding was performed with a
20 μL pipette tip across the horizontal midsection of
each well, and photographs were taken at two points
along each wound. The XY coordinates of each point
were saved using Simple PCI coordinate mapping soft-
ware and photographed again 24 hours after treatment
(described below). The percentage wound closure was
calculated as (1 – (area of wound at 24 hours/area of
wound at time 0)) ×100%, as quantified using ImageJ
software (see Additional file 1: Figure S1). Recombinant
human IGF-I, IGF-II, IGFBP-4 and IGFBP-5 were pur-
chased from R&D Systems (Minneapolis, Minnesota). A
dose response experiment ranging from 2–25 nM IGF-I
or –II established that 2 nM was sufficient to generate a
significant increase in migration of HTR-8/SVneo cells.
Dosage in the range of 1–25 nM IGFBP-4 or −5 was ex-
pected to have inhibitory effects based on the literature
[26] and preliminary experiments. Migration experiments
examining the stimulatory effects of the IGFs were per-
formed by treating HTR-8/SVneo cells for 24 hours with
either 2 nM IGF-I or IGF-II. Migration experiments
examining the inhibitory effects of the IGFBPs were per-
formed by co-treating HTR-8/SVneo cells with either
20 nM IGFBP-4 or IGFBP-5, and one of the two
IGFs at 2 nM. Experiments examining IGF-I potentiating
effects of low doses of IGFBP-5 were performed across a
range of concentrations from equimolar amounts of IGF-I
and IGFBP-5, to an 8 fold excess of IGF-I against IGFBP-5
based on previous work with IGFBP-1 [27,28]. Potentiating
effects of IGFBP-4 were not investigated because we know
of no evidence that IGFBP-4 has IGF-potentiating effects






















Figure 1 Effects of IGF-I and IGF-II dose on migration of HTR-8/
SVneo cells. IGF-I and –II experiments were conducted separately
and therefore have different control values. Values are mean ± standard
error of the mean, and values with different superscript letters
within an experiment are significantly different according to Tukey’s
HSD test (overall variation in IGF-I experiments: F3, 20 = 28.65, P < 0.0001,
N = 6 per treatment; IGF-II experiments: F3, 43 = 12.86, P < 0.0001,

























2 nM IGF-I - + + + - - -
2 nM IGF-II - - - - + + +
20 nM IGFBP-4 - - + - - + -
20 nM IGFBP-5 - - - + - - +
Figure 2 Effects of IGF-I, IGF-II, IGFBP-4 and IGFBP-5 on migration
of HTR-8/SVneo cells. Values are mean ± standard error of the mean,
and values with different superscript letters are significantly different
according to Tukey’s HSD test (overall variation among treatments:
F6, 249 = 38.11, P < 0.0001, N = 24–62 per treatment).
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20 nM IGFBP-5 were also performed.
Immunohistochemistry
Human placental tissue was collected from elective termi-
nations of pregnancies between 5 and 13 weeks of gesta-
tion. Sections from a total of 6 different placentae were
used. Upon collection, samples were fixed overnight in 4%
paraformaldehyde, paraffin-embedded, sectioned (4–5 μm)
and mounted. Sections were deparaffinized in xylene and
rehydrated with a graded series of alcohol. Antigen re-
trieval was performed by heating sections in 10 mM citrate
buffer for 30 min. Immunohistochemical staining was
performed using a horseradish peroxidase- 3-amino-
9-ethylcarbazole (HRP-AEC) goat kit (R&D Systems)
according to the manufacturer’s instructions. Adjacent
sections were incubated with primary polyclonal anti-
human antibodies against one of cluster of differentiation
31 (CD31), PAPP-A2, IGFBP-4 or IGFBP-5, all of which
were raised in goat (R&D Systems). Immunoreactivity was
visualized with AEC and sections were counterstained
with hematoxylin. Negative controls were prepared using
non-specific goat immunoglobulin G (IgG; R&D Systems)
in place of primary antibodies. The use of these sam-
ples was approved by the University of British Columbia
Children’s and Women’s Research Ethics Board, the Mount
Sinai Hospital Research Ethics Board and the Simon Fraser
University Research Ethics Board.
Statistical analyses
Effects of treatments were analyzed in JMP (ver. 10; SAS
Institute Inc.) using a general linear model including the
effects of treatment and date of experiment. Treatment
replicates were distributed across different experimental
dates, with replication both within and between days. All
experiments contained the appropriate controls (controls,
and IGF-I and/or –II alone) to allow for comparison across
dates (with similar sample sizes for treatments performed
on the same day).
Results
IGF-I, IGF-II and HTR-8/SVneo migration
Preliminary experiments with 2 nM, 10 nM or 25 nM of
either IGF-I or IGF-II showed a significant stimulatory ef-
fect of 2 nM on HTR-8/SVneo cells (Figure 1). Treating
HTR-8/SVneo cells with either IGF-I or IGF-II at 2 nM
significantly increased migration compared with controls,
with IGF-I increasing migration significantly more than
IGF-II (Figure 2).
IGFBP-4, IGFBP-5 inhibit effects of IGF-I and IGF-II on
HTR-8/SVneo migration
While IGFBP-4 and −5 both significantly reduced the ef-
fects of 2 nM IGF-I, 20 nM IGFBP-4 almost completelyblocked the effects of 2 nM IGF-I, whereas 20 nM
IGFBP-5 did not (Figure 2). While 2 nM IGF-I in-
creased wound closure to 63%, co-treatment with 20 nM
IGFBP-4 reduced wound closure to 41% compared with
38% in controls, but co-treatment with 20nM IGFBP-5 had
a lesser effect, reducing IGF-I-mediated wound closure to
an intermediate level (56%). Either 20 nM IGFBP-4
or 20 nM IGFBP-5 completely blocked the effects of
2 nM IGF-II (Figure 2). The migration-stimulating effects
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20 nM IGFBP-4 (wound closure 36%) or 20 nM IGFBP-5
(wound closure 42%); neither IGFBP treatment was signifi-
cantly different from controls (38%). There was no signifi-
cant effect of IGFBP-4 or IGFBP-5 alone at 20 nM in
preliminary experiments, suggesting an absence of IGF-
independent effects (data not shown). Moreover, there was
no significant potentiation effect of low doses of IGFBP-5
with 2 nM IGF-I (Figure 3).
Immunoreactivity for IGFBP-4, IGFBP-5 and PAPP-A2 in
the syncytiotrophoblast
The presence of IGFBP-4, IGFBP-5 and PAPP-A2 was
examined in serial sections of placental villi at 5, 6, 7
and 13 weeks of gestation. In addition to the non-
specific goat IgG negative control, staining against CD31
was used as a negative control for immunoreactivity in
the syncytiotrophoblast, since staining was only expected
in the endothelium of fetal vessels. Across all gestational
ages, IGFBP-4 and −5 showed localization within the
syncytiotrophoblast, with stronger immunoreactivity ob-
served for IGFBP-4 than IGFBP-5 (Figure 4). IGFBP-4
and −5 also appeared in the chorionic mesoderm. PAPP-
A2 in contrast, showed little to no immunoreactivity
in the chorionic mesoderm at 5 and 6 weeks, but did
show strong immunoreactivity in the syncytiotrophoblast
(Figure 4).
Discussion
To investigate the potential mechanism underlying the
associations between levels of PAPP-A and PAPP-A2
and pregnancy complications such as PE and IUGR,
we studied the effects of pappalysin substrates IGFBP-4a
b b b
a,b
+ 2 nM IGF-I















Figure 3 Effects of low doses of IGFBP-5 on migration of
HTR-8/SVneo cells. Values are mean ± standard error of the mean,
and values with different superscript letters are significantly different
according to Tukey’s HSD test (overall variation among treatments:
F4, 42 = 4.38, P < 0.0048, N = 6–14 per treatment).and −5 on IGF-I and -II in a model of EVT migration.
We also examined the location and timing of IGFBP-4
and −5 expression to determine whether the pappalysins
might also influence processes occurring within the villi
early in pregnancy.
Consistent with previous findings in various models
of first trimester human EVT [30-36], both IGF-I and
IGF-II at 2 nM significantly stimulated migration of
HTR-8/SVneo cells in a cell-wounding assay. Further-
more, IGF-I had greater stimulatory effects than IGF-II
at this concentration. The difference in effects of IGF-I
and –II may be due to the presence of both type 1 and
type 2 IGF receptors (IGF1R and IGF2R) in HTR-8/
SVneo cells [26,36], and the higher binding affinity of
IGF1R for IGF-I than for IGF-II [37].
IGFBP-4 and −5 showed different levels of IGF inhib-
ition. IGFBP-4 was able to block the migration-stimulating
effects of both IGF-I and IGF-II to control levels. In
contrast, IGFBP-5 was able to inhibit the migration-
stimulating effects of IGF-II to control levels, but only par-
tially inhibited IGF-I. While previous work has shown
IGFBP-5 blocks IGF-II stimulation of migration in a cell
line model of EVT [26], this is to our knowledge the first
data regarding the effects of exogenous IGFBP-4 on
trophoblast migration. IGFBP-4 has however been found
to influence migration and invasion in cancer studies, with
inhibitory or stimulatory effects on migration depending
on the model examined [38-42]. Similarly, the effects of
IGFBP-5 on cellular proliferation and invasion in breast
cancer studies appear to be cell line dependent [43].
The inhibitory effect of IGFBP-4 on trophoblast mi-
gration may, at least in part, underlie the association
between elevated circulating levels of IGFBP-4 in early
pregnancy and the subsequent development of fetal growth
restriction [44].
There was no evidence of potentiation of the effects
of IGF-I by low doses of IGFBP-5, either because no
such effect exists in vivo, or because IGF potentiation re-
quires interaction between IGFBP-5 and the extracellular
matrix [45]. Similarly, the lack of IGF-independent ef-
fects of IGFBP-4 or −5 in our experiments may be due
to a real absence of effects in vivo, to the absence of as-
yet-uncharacterized cell surface IGFBP-4 and −5 recep-
tors in HTR-8/SVneo cells [29], or to a requirement for
interaction with the extracellular matrix [45] or prote-
olysis of the IGFBPs [12,14].
IGF-I and -II have different primary sources in the pla-
centa. IGF-II is strongly expressed by EVT and syncytio-
trophoblast in the human placenta [3,4,23], whereas the
predominant source of IGF-I in the placenta is the ma-
ternal circulation, as it is only weakly expressed by the
placenta [4,23]. Low levels of IGF-I mRNA relative to
IGF-II mRNA have been detected in the cytotrophoblast,
mesodermal core and endothelium of human placental



























Figure 4 Immunoreactivity (red colour) against IGFBP-4, −5, and PAPPA2 in the syncytiotrophoblast of first trimester placental villi.
Serial cross sections of placental villi at 5 and 6 weeks of gestation (7 and 13 weeks not shown) were stained for IGFBP-4, IGFBP-5, and PAPP-A2.
Negative controls used non-specific goat IgG in the place of the primary antibodies. FB = fetal blood vessel, CM = chorionic mesoderm,
ST = syncytiotrophoblast. Scale bars denote 100 μm.
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EVT [30,46,47]. IGF-I has been detected less consistently
at the protein level. In one study, IGF-I protein was
undetectable in human placental lysates [48], and in
another IGF-I protein was detected in first trimester
villous cytotrophoblasts, but at much lower levels than
IGF-II [47].
A number of observations from previous work and
this study suggest that PAPP-A and PAPP-A2 play very
different roles in normal placental development and dis-
ease, which may explain why PAPP-A and PAPP-A2 show
contrasting levels in relation to adverse pregnancy out-
comes (i.e., PAPP-A being down-regulated and PAPP-A2
being upregulated in association with pregnancy complica-
tions [16]). PAPP-A is a protease of both IGFBP-4 and
IGFBP-5, whereas PAPP-A2 only proteolyzes IGFBP-5.
Therefore our data suggest that PAPP-A2 has less of a
stimulatory effect on EVT migration than PAPP-A, as
IGFBP-5 shows less inhibition of IGF-I, which is more
potent than IGF-II. Furthermore, PAPP-A may have astronger effect modulating the availability of IGF-I from
the maternal circulation than PAPP-A2.
PAPP-A and PAPP-A2 are expressed by the syncytio-
trophoblast as well as invasive EVT [49,50]. It was previ-
ously thought that the only location of expression of
IGFBP-4 and −5 in the first trimester was the maternal
decidua, since IGFBP-5 had only been observed in villi
in the second and third trimester [23]. More recently,
IGFBP-4 immunoreactivity has been observed in the
chorionic mesoderm of placental villi at 10–13 weeks
[44]. Here, we show that IGFBP-4 and −5 are present in
the syncytiotrophoblast of placental villi as early as
5 weeks of gestation. PAPP-A and PAPP-A2 may there-
fore influence aspects of early placental development in
addition to the EVT invasion of the decidua and remod-
eling of the spiral arteries, e.g., cytotrophoblast prolifera-
tion or fusion with the syncytiotrophoblast. While we do
not know whether the placentae we sampled were from
pregnancies that would have gone on to develop preg-
nancy complications, we observed consistent results in
Crosley et al. Reproductive Biology and Endocrinology 2014, 12:123 Page 6 of 7
http://www.rbej.com/content/12/1/1236 different placentae, 3 of which were at a gestational
age of 7 weeks or less. It is very unlikely that none of
these early placentae were from a healthy, uncompli-
cated pregnancy.
Conclusions
IGFBP-4 and −5 have differing effects on IGF-I and -II
in an in vitro model of EVT migration. Given that
PAPP-A and PAPP-A2 show contrasting patterns of
regulation in adverse pregnancy outcomes, we propose that
the stimulatory effects of PAPP-A2 on EVT migration may
be less than those of PAPP-A, and that PAPP-A2 may
function principally to modulate IGF-II produced locally in
the placenta via its effects on IGFBP-5. Moreover, given
the lack of IGF-independent and potentiating effects of the
pappalysin substrates, we propose that the effects of the
pappalysins are principally stimulatory on migration. This
hypothesis suggests that low PAPP-A levels in early preg-
nancy may contribute to placental pathology, whereas high
PAPP-A2 levels in pregnancies that go on to develop com-
plications may represent a compensatory response [51,52].
Additional file
Additional file 1: Figure S1. HTR-8/SVneo cell wounding assay.
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